X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
Two manuscripts published back to back detail the full results from the BE RADIANT and BE SURE studies, comparing the efficacy and safety of bimekizumab to secukinumab and adalimumab, respectively
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
This will include 11 e-posters and an oral presentation of late-breaking data from the Phase 3b BE RADIANT study evaluating the efficacy and safety of bimekizumab compared to secukinumab in the treatment of moderate to severe plaque psoriasis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
